Characterization of a Novel Pathogenic PLCG2 Variant Leading to APLAID Syndrome Responsive to a TNF Inhibitor.

Yang Z, Tao P, Han X, Kozlova A, He T, Volchkov E, Nesterenko Z, Pershin D, Raykina E, Fatkhudinov T, Korobeynikova A, Aksentijevich I, Yang J, Shcherbina A, Zhou Q, Yu X

Open source

DOI
10.1002/art.42948
Published
2024 Nov
Container
Arthritis & rheumatology (Hoboken, N.J.)
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1002/art.42948,
  title = {Characterization of a Novel Pathogenic PLCG2 Variant Leading to APLAID Syndrome Responsive to a TNF Inhibitor.},
  author = {Yang Z and Tao P and Han X and Kozlova A and He T and Volchkov E and Nesterenko Z and Pershin D and Raykina E and Fatkhudinov T and Korobeynikova A and Aksentijevich I and Yang J and Shcherbina A and Zhou Q and Yu X},
  year = {2024},
  journal = {Arthritis \& rheumatology (Hoboken, N.J.)},
  doi = {10.1002/art.42948},
  url = {https://doi.org/10.1002/art.42948}
}

RIS

TY  - JOUR
TI  - Characterization of a Novel Pathogenic PLCG2 Variant Leading to APLAID Syndrome Responsive to a TNF Inhibitor.
AU  - Yang Z
AU  - Tao P
AU  - Han X
AU  - Kozlova A
AU  - He T
AU  - Volchkov E
AU  - Nesterenko Z
AU  - Pershin D
AU  - Raykina E
AU  - Fatkhudinov T
AU  - Korobeynikova A
AU  - Aksentijevich I
AU  - Yang J
AU  - Shcherbina A
AU  - Zhou Q
AU  - Yu X
PY  - 2024
JO  - Arthritis & rheumatology (Hoboken, N.J.)
DO  - 10.1002/art.42948
UR  - https://doi.org/10.1002/art.42948
ER  - 

APA

Z, Y., P, T., X, H., A, K., T, H., E, V., Z, N., D, P., E, R., T, F., A, K., I, A., J, Y., A, S., Q, Z., & X, Y. (2024). Characterization of a Novel Pathogenic PLCG2 Variant Leading to APLAID Syndrome Responsive to a TNF Inhibitor.. Arthritis & rheumatology (Hoboken, N.J.). https://doi.org/10.1002/art.42948

Source records